Cartesian Therapeutics (RNAC) EBIAT (2016 - 2025)
Historic EBIAT for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$35.9 million.
- Cartesian Therapeutics' EBIAT fell 4845.97% to -$35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.0 million, marking a year-over-year increase of 8040.31%. This contributed to the annual value of -$77.4 million for FY2024, which is 6476.08% up from last year.
- Latest data reveals that Cartesian Therapeutics reported EBIAT of -$35.9 million as of Q3 2025, which was down 4845.97% from $15.9 million recorded in Q2 2025.
- Cartesian Therapeutics' 5-year EBIAT high stood at $28.8 million for Q1 2022, and its period low was -$177.7 million during Q4 2023.
- In the last 5 years, Cartesian Therapeutics' EBIAT had a median value of -$10.3 million in 2024 and averaged -$17.1 million.
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 311472.93% in 2023, then soared by 22150.7% in 2024.
- Quarter analysis of 5 years shows Cartesian Therapeutics' EBIAT stood at $12.2 million in 2021, then tumbled by 51.85% to $5.9 million in 2022, then crashed by 3114.73% to -$177.7 million in 2023, then skyrocketed by 94.23% to -$10.3 million in 2024, then tumbled by 250.16% to -$35.9 million in 2025.
- Its last three reported values are -$35.9 million in Q3 2025, $15.9 million for Q2 2025, and -$17.7 million during Q1 2025.